Health Care·Biotechnology·$4.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.37 | N/A | -18.82% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.37 | N/A | -18.82% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about current performance but remains committed to their strategic objectives. They highlighted the importance of their ongoing research and development efforts.
Management acknowledged the challenges faced during the quarter.
They emphasized ongoing efforts to advance their pipeline despite setbacks.
There was a focus on long-term goals rather than short-term results.
The earnings report indicates that CRISPR Therapeutics faced challenges this quarter, particularly reflected in the EPS miss. Despite this, the stock rose by 1.26%, suggesting that investors may be optimistic about the company's long-term potential and ongoing projects. The lack of revenue data and guidance leaves some uncertainty about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
UDR INC REIT
Feb 9, 2026